As an end-to-end CDMO company, Porton will present its customized R&D and GMP manufacturing services to pharmaceutical and biotech clients, as well as research institutions worldwide.
Founded in 2005, Porton Pharma Solutions provides end-to-end, customized R&D and GMP manufacturing services to pharmaceutical and biotech companies, as well as research institutions worldwide, spanning the entire drug lifecycle from preclinical development to commercialization.
Our capabilities cover both drug substances and drug products across multiple modalities, including Small Molecules, TIDES, Biologics and Conjugates, and Advanced Therapy Medicinal Products. As of June 30, 2026, Porton had over 4,400 employees globally, built partnerships with more than 1,500 customers, and successfully delivered approximately 6,000 projects. We are committed to a customer-centric approach, delivering innovative and reliable global CDMO solutions, enabling earlier access to good medicines.
-
Small Molecules CDMO Services
This platform delivers full‑scope CMC solutions for small‑molecule drug programs. Our end‑to‑end CDMO capabilities cover:
‑ Process development and manufacturing for intermediates and Drug Substance (DS)
‑ Formulation development and Drug Product (DP) manufacturing
‑ Comprehensive quality‑related studies
‑ IND / NDA regulatory filing support
-
TIDES CDMO Services
Porton’s one-stop peptide & oligonucleotide drug CDMO service platform provides comprehensive services for peptide drugs and small nucleic acid drugs. Our capabilities cover:
‑ Early stage research
‑ Process development and manufacturing
‑ Formulation development and Drug Product (DP) manufacturing
‑ Analytical method development and validation
‑ Global regulatory affairs support
-
Biologics and Conjugates CDMO Services
Porton’s end‑to‑end biologics and conjugates CDMO platform delivers comprehensive solutions for biologic molecules and conjugate therapeutics (ADC, AOC, DAC, PDC, RDC). Our capabilities cover:
‑ Early‑stage research
‑ Process development and manufacturing
‑ Formulation development and Drug Product (DP) manufacturing
‑ Analytical method development and validation
‑ Global regulatory support for new drug registrations
For more information, visit www.portonpharma.com
Contact us: business@portonpharma.com
Learn how we empowering the full lifecycle of drug development: https://www.chemistry-today.com/articles/empowering-the-full-lifecycle-of-drug-development/
